Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lenalidomide

FDA-approved product (capsule, oral), marketed as Lenalidomide, Revlimid.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Lenalidomide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anemia
  • Anemia (phenotype)
  • Immune system disease
  • Mantle cell lymphoma
  • Multiple myeloma
  • Myelodysplastic syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other immunosuppressants
FDA pharmacologic class
Thalidomide Analog FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA27.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli25.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lenalidomide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lenalidomide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

    NCT07562022 · start 2026-06-09

    Registered record
    Registry ID
    NCT07562022
    Conditions
    Follicular Lymphoma (FL)
    Interventions
    SCTB35 injection; Rituximab; Lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-06-09
    Completion
    2029-06
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFollicular Lymphoma (FL)
    InterventionSCTB35 injection; Rituximab; Lenalidomide
    PhasePhase 3
    Registry statusRecruiting

  • To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma

    NCT06742138 · start 2025-01

    Registered record
    Registry ID
    NCT06742138
    Conditions
    Multiple Myeloma
    Interventions
    QL2109; Pomalidomide; Dexamethasone; DARZALEX FASPRO®
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2025-01
    Completion
    2028-12
    Enrolment
    284

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionQL2109; Pomalidomide; Dexamethasone; DARZALEX FASPRO®
    PhasePhase 3
    Registry statusNot yet recruiting

  • Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

    NCT05231629 · start 2023-12-13

    Registered record
    Registry ID
    NCT05231629
    Conditions
    Multiple Myeloma
    Interventions
    Dara-VRd intensification, Dara-R maintenance; AHCT intensification, Dara-R maintenance; AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance; AHCT intensification, Dara-R consolidation, Dara-R maintenance; Dara-VRd induction
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-12-13
    Completion
    2029-12
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionDara-VRd intensification, Dara-R maintenance; AHCT intensification, Dara-R maintenance; AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance; AHCT intensification, Dara-R consolidation, Dara-R maintenance +1 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

    NCT05827016 · start 2023-06-22

    Registered record
    Registry ID
    NCT05827016
    Conditions
    Multiple Myeloma
    Interventions
    Iberdomide; Lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2023-06-22
    Completion
    2036-01-01
    Enrolment
    1,230

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionIberdomide; Lenalidomide
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma

    NCT05860036 · start 2023-04-04

    Registered record
    Registry ID
    NCT05860036
    Conditions
    Multiple Myeloma
    Interventions
    anti-BCMA CAR-T; VRd
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-04-04
    Completion
    2028-03-10
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    Interventionanti-BCMA CAR-T; VRd
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

    NCT05259839 · start 2022-10-20

    Registered record
    Registry ID
    NCT05259839
    Conditions
    Relapsed/Refractory Multiple Myeloma
    Interventions
    Etentamig; Dexamethasone; Lenalidomide; Pomalidomide; Daratumumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2022-10-20
    Completion
    2033-09
    Enrolment
    283

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed/Refractory Multiple Myeloma
    InterventionEtentamig; Dexamethasone; Lenalidomide; Pomalidomide +1 more
    PhasePhase 1
    Registry statusActive not recruiting

  • Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM

    NCT07150091 · start 2022-07-19

    Registered record
    Registry ID
    NCT07150091
    Conditions
    Multiple Myeloma
    Interventions
    Belantamab mafodotin; Nirogacestat; Lenalidomide; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2022-07-19
    Completion
    2027-03-11
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionBelantamab mafodotin; Nirogacestat; Lenalidomide; Dexamethasone
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.

    NCT06321640 · start 2022-07-08

    Registered record
    Registry ID
    NCT06321640
    Conditions
    Breast Cancer; Lung Cancer; Melanoma; Head and Neck Cancer; Urothelial Carcinoma; Colorectal Cancer; Liver Metastases; Lung Metastases
    Interventions
    Cohort A: primarily operable disease, candidate to adjuvant; Cohort B: locally advanced disease; Cohort C: metastatic disease; Cohort D: Progressive disease; Cohort E: Hematological neoplasms; Cohort F: Toxicity
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-07-08
    Completion
    2025-12-31
    Enrolment
    265

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Lung Cancer; Melanoma; Head and Neck Cancer +4 more
    InterventionCohort A: primarily operable disease, candidate to adjuvant; Cohort B: locally advanced disease; Cohort C: metastatic disease; Cohort D: Progressive disease +2 more
    PhaseNot recorded
    Registry statusUnknown

  • A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

    NCT05298683 · start 2022-05

    Registered record
    Registry ID
    NCT05298683
    Conditions
    Multiple Myeloma; Renal Impairment; Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases
    Interventions
    Isatuximab; Pomalidomide; Dexamethasone; Acetaminophen (paracetamol); Ranitidine (or equivalent); Diphenhydramine (or equivalent)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-05
    Completion
    2026-01
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma; Renal Impairment; Neoplasms, Plasma Cell; Neoplasms by Histologic Type +4 more
    InterventionIsatuximab; Pomalidomide; Dexamethasone; Acetaminophen (paracetamol) +2 more
    PhasePhase 2
    Registry statusUnknown

  • A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

    NCT05147493 · start 2022-04

    Registered record
    Registry ID
    NCT05147493
    Conditions
    Multiple Myeloma; Renal Impairment; Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases
    Interventions
    Isatuximab; Bortezomib; Cyclophosphamide; Dexamethasone; Lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-04
    Completion
    2025-02
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma; Renal Impairment; Neoplasms, Plasma Cell; Neoplasms by Histologic Type +4 more
    InterventionIsatuximab; Bortezomib; Cyclophosphamide; Dexamethasone +1 more
    PhasePhase 2
    Registry statusUnknown

  • Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT

    NCT05497102 · start 2021-11-08

    Registered record
    Registry ID
    NCT05497102
    Conditions
    Multiple Myeloma
    Interventions
    Lenalidomide maintenance
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-11-08
    Completion
    2025-12
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionLenalidomide maintenance
    PhasePhase 2
    Registry statusUnknown

  • Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma

    NCT04635189 · start 2021-07-27

    Registered record
    Registry ID
    NCT04635189
    Conditions
    Multiple Myeloma
    Interventions
    Daratumumab; Lenalidomide; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-07-27
    Completion
    2027-09-08
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionDaratumumab; Lenalidomide; Dexamethasone
    PhasePhase 2
    Registry statusActive not recruiting

  • RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL

    NCT05425654 · start 2021-05-17

    Registered record
    Registry ID
    NCT05425654
    Conditions
    Primary CNS Lymphoma
    Interventions
    Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-05-17
    Completion
    2026-05
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary CNS Lymphoma
    InterventionRituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide
    PhasePhase 2
    Registry statusUnknown

  • Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL

    NCT04697160 · start 2020-04-01

    Registered record
    Registry ID
    NCT04697160
    Conditions
    Diffuse Large B Cell Lymphoma
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-04-01
    Completion
    2021-05-07
    Enrolment
    3,573

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Large B Cell Lymphoma
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

    NCT04091126 · start 2019-12-18

    Registered record
    Registry ID
    NCT04091126
    Conditions
    Multiple Myeloma
    Interventions
    Belantamab mafodotin; Bortezomib; Lenalidomide; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2019-12-18
    Completion
    2026-12-31
    Enrolment
    118

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionBelantamab mafodotin; Bortezomib; Lenalidomide; Dexamethasone
    PhasePhase 1
    Registry statusActive not recruiting